ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026
Treatment and Outcomes of Crohn's Disease and Ulcerative Colitis in Newly Diagnosed Adults in the United States, 2007 to 2023.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cancer Risk With Advanced Therapies in Patients With Inflammatory Bowel Diseases: An Administrative Claims-Based Study.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND &
aimsWe examined treatment and outcomes of inflammatory bowel diseases (IBDs) in a contemporary and diverse cohort of adults with newly diagnosed IBD in a large, commercially insured United States population.
methodsUsing an administrative claims database (OptumLabs Data Warehouse), we created an inception cohort of physician-diagnosed IBD between 2007 and 2023. We examined cumulative incidence of hospitalization, surgery, safety events, and medication use in patients with Crohn's disease (CD) and ulcerative colitis (UC).
resultsAmong 3044 adults with newly diagnosed CD (age at diagnosis, 39 ± 15 years; 47% male; 83% White, 7.5% Black, and 7.1% Hispanic patients) followed over a mean 4.3 ± 3.1 years, 5-year risk of IBD-related hospitalization, major surgery, and serious infections was 16%, 12%, and 13%, respectively, with no consistent racial and ethnic, age, or sex differences. In patients diagnosed between 2019 and 2023, 1-year cumulative use of corticosteroids and advanced therapy was 44% (22% with ≥2 courses) and 53%, respectively, without significant racial and ethnic, age, or sex differences. Among 3893 patients with newly diagnosed UC (age at diagnosis, 41 ± 14 years; 52% male; 80% White, 7.2% Black, and 8.2% Hispanic patients) followed over 4.2 ± 3.0 years, 5-year risk of IBD-related hospitalization, colectomy, and serious infection was 11%, 6%, and 10%, respectively, with lower risk in Hispanic patients (vs White patients). In patients diagnosed between 2019 and 2023, 1-year cumulative use of corticosteroids and advanced therapy was 47% (26% with ≥2 courses) and 27%, respectively, with earlier initiation of advanced therapies in more recent time periods, and with lower utilization of advanced therapies in Hispanic patients.
conclusionsIn a contemporary and diverse cohort of commercially insured adults with newly diagnosed IBD in the United States, excess corticosteroid use is decreasing in recent era, along with early initiation of advanced therapies. No consistent racial and ethnic, age, or sex differences were identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.